Vidaza Unione Europea - rumeno - EMA (European Medicines Agency)

vidaza

bristol-myers squibb pharma eeig - azacitidină - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agenți antineoplazici - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

AZACITIDINA MSN 25 mg/ml Romania - rumeno - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

azacitidina msn 25 mg/ml

pharmadox healthcare ltd. - malta - azacitidinum - pulb. pt. susp. inj. - 25 mg/ml - antimetaboliti analogi ai bazelor pirimidinice

Onureg Unione Europea - rumeno - EMA (European Medicines Agency)

onureg

bristol-myers squibb pharma eeig - azacitidină - leucemie, mieloidă, acută - agenți antineoplazici - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

AZACITIDINA STADA 25 mg/ml Romania - rumeno - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

azacitidina stada 25 mg/ml

pharmadox healthcare ltd. - malta - azacitidinum - pulb. pt. susp. inj. - 25mg/ml - antimetaboliti analogi ai bazelor pirimidinice